JP2012507499A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012507499A5 JP2012507499A5 JP2011533849A JP2011533849A JP2012507499A5 JP 2012507499 A5 JP2012507499 A5 JP 2012507499A5 JP 2011533849 A JP2011533849 A JP 2011533849A JP 2011533849 A JP2011533849 A JP 2011533849A JP 2012507499 A5 JP2012507499 A5 JP 2012507499A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- amino acid
- acid sequence
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11193208P | 2008-11-06 | 2008-11-06 | |
| US61/111,932 | 2008-11-06 | ||
| PCT/IB2009/007351 WO2010052556A1 (en) | 2008-11-06 | 2009-11-05 | Treatment with anti-alpha2 integrin antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015062978A Division JP2015145397A (ja) | 2008-11-06 | 2015-03-25 | 抗α２インテグリン抗体を使用する処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012507499A JP2012507499A (ja) | 2012-03-29 |
| JP2012507499A5 true JP2012507499A5 (enExample) | 2012-12-27 |
| JP5775458B2 JP5775458B2 (ja) | 2015-09-09 |
Family
ID=41528529
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533849A Expired - Fee Related JP5775458B2 (ja) | 2008-11-06 | 2009-11-05 | 抗α２インテグリン抗体を使用する処置 |
| JP2015062978A Pending JP2015145397A (ja) | 2008-11-06 | 2015-03-25 | 抗α２インテグリン抗体を使用する処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015062978A Pending JP2015145397A (ja) | 2008-11-06 | 2015-03-25 | 抗α２インテグリン抗体を使用する処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8298531B2 (enExample) |
| EP (1) | EP2346903A1 (enExample) |
| JP (2) | JP5775458B2 (enExample) |
| AU (1) | AU2009312532B2 (enExample) |
| CA (1) | CA2742899A1 (enExample) |
| CL (1) | CL2011000931A1 (enExample) |
| DK (1) | DK201170284A (enExample) |
| EA (1) | EA201190002A1 (enExample) |
| MX (1) | MX2011004696A (enExample) |
| NZ (1) | NZ592436A (enExample) |
| WO (1) | WO2010052556A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010052556A1 (en) * | 2008-11-06 | 2010-05-14 | Glenmark Pharmaceuticals S.A. | Treatment with anti-alpha2 integrin antibodies |
| TWI560199B (en) * | 2010-08-31 | 2016-12-01 | Sanofi Sa | Peptide or peptide complex binding to α2 integrin and methods and uses involving the same |
| EP3604339B1 (en) | 2011-01-14 | 2021-03-10 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| AU2012255143A1 (en) * | 2011-05-19 | 2014-02-20 | The Regents Of The University Of Michigan | Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation |
| JP7462566B2 (ja) * | 2018-03-16 | 2024-04-05 | ブリストル－マイヤーズ スクイブ カンパニー | タンパク質生産の間の代謝酵素活性およびジスルフィド結合還元 |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| HUE065344T2 (hu) * | 2018-03-19 | 2024-05-28 | Regeneron Pharma | Mikrochip kapilláris elektroforézis assay-k és reagensek |
| EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| US20230055235A1 (en) * | 2019-12-27 | 2023-02-23 | Interoligo Corporation. | Anti-cancer immunotherapeutic composition for treating cancer |
| US20240317873A1 (en) * | 2021-03-16 | 2024-09-26 | City Of Hope | Anti-hvem antibodies |
| CN114807038B (zh) * | 2022-02-11 | 2023-11-10 | 四川大学华西第二医院 | 一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用 |
| EP4545563A1 (en) * | 2022-06-27 | 2025-04-30 | Foreseen Technology (Beijing) Co., Ltd. | Antibodies targeting itga2 and antibody-drug conjugates comprising same |
| EP4722245A1 (en) * | 2023-06-02 | 2026-04-08 | Foreseen Technology (Beijing) Co., Ltd. | Antibody targeting itga2, antibody drug conjugate thereof, and use |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5858709A (en) | 1996-10-15 | 1999-01-12 | Smithkline Beecham P.L.C. | Fibronectin binding protein B compounds |
| US20020160970A1 (en) | 1996-04-10 | 2002-10-31 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| AU2006315037C1 (en) * | 2005-11-18 | 2013-05-02 | Ichnos Sciences SA | Anti-alpha2 integrin antibodies and their uses |
| BRPI0620316A2 (pt) * | 2005-12-21 | 2011-11-08 | Wyeth Corp | formulações de proteìnas com viscosidades reduzida e seus usos |
| US20080267978A1 (en) * | 2006-08-28 | 2008-10-30 | Mary Zutter | Anti-angiogenic targets for cancer therapy |
| WO2010052556A1 (en) * | 2008-11-06 | 2010-05-14 | Glenmark Pharmaceuticals S.A. | Treatment with anti-alpha2 integrin antibodies |
-
2009
- 2009-11-05 WO PCT/IB2009/007351 patent/WO2010052556A1/en not_active Ceased
- 2009-11-05 JP JP2011533849A patent/JP5775458B2/ja not_active Expired - Fee Related
- 2009-11-05 CA CA2742899A patent/CA2742899A1/en not_active Abandoned
- 2009-11-05 EA EA201190002A patent/EA201190002A1/ru unknown
- 2009-11-05 NZ NZ592436A patent/NZ592436A/xx not_active IP Right Cessation
- 2009-11-05 AU AU2009312532A patent/AU2009312532B2/en not_active Ceased
- 2009-11-05 EP EP09756355A patent/EP2346903A1/en not_active Withdrawn
- 2009-11-05 MX MX2011004696A patent/MX2011004696A/es active IP Right Grant
- 2009-11-06 US US12/614,178 patent/US8298531B2/en not_active Expired - Fee Related
-
2011
- 2011-04-26 CL CL2011000931A patent/CL2011000931A1/es unknown
- 2011-06-06 DK DKPA201170284A patent/DK201170284A/en not_active Application Discontinuation
-
2012
- 2012-08-23 US US13/593,285 patent/US20130084285A1/en not_active Abandoned
-
2015
- 2015-03-25 JP JP2015062978A patent/JP2015145397A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012507499A5 (enExample) | ||
| DK201170284A (en) | Treatment with anti-alpha2 integrin antibodies | |
| JP7798932B2 (ja) | 癌の治療のためのクローディン１８．２に対する抗体を含む治療法 | |
| CN109153724B (zh) | 通过施用pd-1抑制剂治疗皮肤癌的方法 | |
| TWI417106B (zh) | 巨噬細胞-刺激蛋白質受體（ｒｏｎ）之抑制及其治療方法 | |
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| JP2019506403A5 (enExample) | ||
| JP2018536624A5 (enExample) | ||
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| RU2009110102A (ru) | Лечение опухолей с помощью антитела к vegf | |
| JP2017510559A5 (enExample) | ||
| JP2012102109A5 (enExample) | ||
| JP2013510868A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| CA2976638A1 (en) | Methods, compositions, and kits for treatment of cancer | |
| WO2021231639A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| JP2022526420A5 (enExample) | ||
| IL292758A (en) | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer | |
| JP2020511481A5 (enExample) | ||
| CN106068126A (zh) | 用于癌症的抗‑met联合抗‑vegfr2抗体的疗法 | |
| CN108350080A (zh) | 用于癌症的联合疗法 | |
| JP2022526841A5 (enExample) | ||
| US20220143228A1 (en) | Her3 radioimmunotherapy for the treatment of solid cancers | |
| WO2021129616A1 (zh) | 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法 | |
| EP4408464A1 (en) | Methods of treating cancer and the pharmaceutical compositions thereof |